Fundamental Analysis of LARIMAR THERAPEUTICS INC(NASDAQ:LRMR) stock

Fundamental Rating

Taking everything into account, LRMR scores 3 out of 10 in our fundamental rating. LRMR was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LRMR as it has an excellent financial health rating, but there are worries on the profitability. LRMR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LRMR has reported negative net income.

LRMR had a negative operating cash flow in the past year.

LRMR had negative earnings in each of the past 5 years.

LRMR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

LRMR's Return On Assets of -29.57% is fine compared to the rest of the industry. LRMR outperforms 69.03% of its industry peers.

With a decent Return On Equity value of -32.65%, LRMR is doing good in the industry, outperforming 77.52% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-29.57%
ROE	-32.65%
ROIC	N/A

ROA(3y)-43.61%

ROA(5y)-45.54%

ROE(3y)-51.91%

ROE(5y)-57.56%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LRMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for LRMR has been increased compared to 1 year ago.

LRMR has more shares outstanding than it did 5 years ago.

LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

LRMR has an Altman-Z score of 6.45. This indicates that LRMR is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.45, LRMR belongs to the best of the industry, outperforming 82.65% of the companies in the same industry.

LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.45

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

LRMR has a Current Ratio of 13.10. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.

LRMR has a Current ratio of 13.10. This is amongst the best in the industry. LRMR outperforms 86.90% of its industry peers.

A Quick Ratio of 13.10 indicates that LRMR has no problem at all paying its short term obligations.

LRMR's Quick ratio of 13.10 is amongst the best of the industry. LRMR outperforms 87.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.1
Quick Ratio	13.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LRMR have decreased strongly by -51.32% in the last year.

EPS 1Y (TTM)-51.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-14.29%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

LRMR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.49% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-40.24%

EPS Next 2Y-36.17%

EPS Next 3Y-33.53%

EPS Next 5Y13.49%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LRMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LRMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LRMR's earnings are expected to decrease with -33.53% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-36.17%

EPS Next 3Y-33.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LRMR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (12/18/2024, 11:56:08 AM)

4.095

-0.23 (-5.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap261.30M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.57%
ROE	-32.65%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	13.1
Quick Ratio	13.1
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-51.32%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-40.24%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LARIMAR THERAPEUTICS INC (LRMR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens